Evaluating the effectiveness of deucravacitinib for moderate plaque psoriasis in China
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
This study is testing how well a new medication called deucravacitinib works for adults with moderate plaque psoriasis in China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | deucravacitinib |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06512337 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze real-world data regarding the effectiveness of deucravacitinib in treating adults with moderate plaque psoriasis in China. Participants will be adults aged 18 and older who have been diagnosed with moderate plaque psoriasis and are starting treatment with deucravacitinib. The study will focus on assessing the treatment's impact on the severity of the condition as reported by dermatologists. Data will be gathered to understand how well the medication works in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a physician-confirmed diagnosis of moderate plaque psoriasis.
Not a fit: Patients who are currently participating in other interventional clinical trials or using other systemic treatments for psoriasis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of deucravacitinib for patients with moderate plaque psoriasis.
How similar studies have performed: While this study focuses on real-world data collection, similar studies evaluating other treatments for plaque psoriasis have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant aged 18 years or older * Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% * Participant newly initiated deucravacitinib according to the label * Provided written informed consent to participate in the study Exclusion Criteria: * Participating in or planning to participate in an interventional clinical trial * Concomitant use of other systemic treatments for psoriasis at baseline * Prior treatment of deucravacitinib
Where this trial is running
Guangzhou, Guangdong
- Dermatology Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.